Dynacure, a French Phase 1/2 biotech developing therapies for neuromuscular diseases, withdrew its plans for an initial public offering on Monday, following its postponement last week. It had filed to raise $100 million by offering 6.3 million shares at a price range of $15 to $17.
The Illkirch-Graffenstaden, France-based company was founded in 2016 and had planned to list on the Nasdaq under the symbol DYCU. J.P. Morgan, BofA Securities, and Wells Fargo Securities were set to be the joint bookrunners on the deal.
